Cannara Biotech Past Earnings Performance
Past criteria checks 5/6
Cannara Biotech has been growing earnings at an average annual rate of 78%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 57.9% per year. Cannara Biotech's return on equity is 7.8%, and it has net margins of 8.5%.
Key information
78.0%
Earnings growth rate
78.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 57.9% |
| Return on equity | 7.8% |
| Net Margin | 8.5% |
| Last Earnings Update | 29 Feb 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Cannara Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Feb 24 | 73 | 6 | 17 | 1 |
| 30 Nov 23 | 66 | 9 | 15 | 1 |
| 31 Aug 23 | 57 | 7 | 14 | 1 |
| 31 May 23 | 51 | 5 | 13 | 1 |
| 28 Feb 23 | 45 | 3 | 11 | 1 |
| 30 Nov 22 | 40 | 3 | 11 | 1 |
| 31 Aug 22 | 36 | 2 | 10 | 1 |
| 31 May 22 | 30 | 1 | 10 | 1 |
| 28 Feb 22 | 27 | 1 | 9 | 1 |
| 30 Nov 21 | 22 | 1 | 8 | 2 |
| 31 Aug 21 | 17 | -2 | 7 | 2 |
| 31 May 21 | 11 | -7 | 7 | 2 |
| 28 Feb 21 | 5 | -11 | 7 | 3 |
| 30 Nov 20 | 3 | -13 | 8 | 3 |
| 31 Aug 20 | 3 | -12 | 9 | 3 |
| 31 May 20 | 3 | -12 | 11 | 2 |
| 29 Feb 20 | 2 | -12 | 12 | 1 |
| 30 Nov 19 | 2 | -13 | 11 | 0 |
| 31 Aug 19 | 2 | -12 | 11 | 0 |
| 31 Aug 18 | 1 | -4 | 4 | 0 |
Quality Earnings: LOVF.F has high quality earnings.
Growing Profit Margin: LOVF.F's current net profit margins (8.5%) are higher than last year (7.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LOVF.F has become profitable over the past 5 years, growing earnings by 78% per year.
Accelerating Growth: LOVF.F's earnings growth over the past year (84.8%) exceeds its 5-year average (78% per year).
Earnings vs Industry: LOVF.F earnings growth over the past year (84.8%) exceeded the Pharmaceuticals industry -13.2%.
Return on Equity
High ROE: LOVF.F's Return on Equity (7.8%) is considered low.